MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval Written by Petra Hegmann on 20th December 2021. Posted in Client News. Previous Next